EAU Guidelines on Neuro-Urology

B. Blok (Chair), D. Castro-Diaz, G. Del Popolo, J. Groen, R. Hamid, G. Karsenty, T.M. Kessler, S. Musco, B. Padilla-Fernández, J. Pannek (Vice-chair)

Guidelines Associates: H. Ecclestone, D. Frings, A. Sartori

Patient representatives: P. de Keijzer, A. van der Vorm

Guidelines Office: N. Schouten
# TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>1. INTRODUCTION</th>
<th>PAGE</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.1 Aim and objectives</td>
<td>4</td>
</tr>
<tr>
<td>1.2 Panel composition</td>
<td>4</td>
</tr>
<tr>
<td>1.3 Available publications</td>
<td>4</td>
</tr>
<tr>
<td>1.4 Publication history</td>
<td>4</td>
</tr>
<tr>
<td>1.5 Background</td>
<td>4</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>2. METHODS</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>2.1 Introduction</td>
<td>4</td>
</tr>
<tr>
<td>2.2 Review</td>
<td>5</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>3. THE GUIDELINE</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>3.1 Epidemiology, aetiology and pathophysiology</td>
<td>5</td>
</tr>
<tr>
<td>3.1.1 Introduction</td>
<td>5</td>
</tr>
<tr>
<td>3.2 Classification systems</td>
<td>7</td>
</tr>
<tr>
<td>3.2.1 Introduction</td>
<td>7</td>
</tr>
<tr>
<td>3.3 Diagnostic evaluation</td>
<td>7</td>
</tr>
<tr>
<td>3.3.1 Introduction</td>
<td>7</td>
</tr>
<tr>
<td>3.3.2 Classification systems</td>
<td>7</td>
</tr>
<tr>
<td>3.3.3 Timing of diagnosis and treatment</td>
<td>8</td>
</tr>
<tr>
<td>3.3.4 Patient history</td>
<td>8</td>
</tr>
<tr>
<td>3.3.4.1 Bladder diaries</td>
<td>9</td>
</tr>
<tr>
<td>3.3.5 Patient quality of life questionnaires</td>
<td>9</td>
</tr>
<tr>
<td>3.3.5.1 Available Questionnaires</td>
<td>10</td>
</tr>
<tr>
<td>3.3.6 Physical examination and additional tests</td>
<td>11</td>
</tr>
<tr>
<td>3.3.6.1 Autonomic dysreflexia</td>
<td>11</td>
</tr>
<tr>
<td>3.3.6.2 Summary of evidence and recommendations for history taking and physical examination</td>
<td>12</td>
</tr>
<tr>
<td>3.3.7 Urodynamics</td>
<td>13</td>
</tr>
<tr>
<td>3.3.7.1 Introduction</td>
<td>13</td>
</tr>
<tr>
<td>3.3.7.2 Urodynamic tests</td>
<td>13</td>
</tr>
<tr>
<td>3.3.7.3 Specialist uro-neurophysiological tests</td>
<td>14</td>
</tr>
<tr>
<td>3.3.7.4 Summary of evidence and recommendations for uro-dynamics and uro-neurophysiology</td>
<td>14</td>
</tr>
<tr>
<td>3.3.8 Renal function</td>
<td>14</td>
</tr>
<tr>
<td>3.4 Disease management</td>
<td>15</td>
</tr>
<tr>
<td>3.4.1 Introduction</td>
<td>15</td>
</tr>
<tr>
<td>3.4.2 Non-invasive conservative treatment</td>
<td>15</td>
</tr>
<tr>
<td>3.4.2.1 Assisted bladder emptying - Credé manoeuvre, Valsalva manoeuvre, triggered reflex voiding</td>
<td>15</td>
</tr>
<tr>
<td>3.4.2.2 Neuro-urological rehabilitation</td>
<td>15</td>
</tr>
<tr>
<td>3.4.2.2.1 Bladder rehabilitation including electrical stimulation</td>
<td>15</td>
</tr>
<tr>
<td>3.4.2.3 Drug treatment</td>
<td>16</td>
</tr>
<tr>
<td>3.4.2.3.1 Drugs for storage symptoms</td>
<td>16</td>
</tr>
<tr>
<td>3.4.2.3.2 Drugs for voiding symptoms</td>
<td>17</td>
</tr>
<tr>
<td>3.4.2.4 Summary of evidence and recommendations for drug treatments</td>
<td>17</td>
</tr>
<tr>
<td>3.4.2.5 Minimally invasive treatment</td>
<td>18</td>
</tr>
<tr>
<td>3.4.2.5.1 Catheterisation</td>
<td>18</td>
</tr>
<tr>
<td>3.4.2.5.2 Summary of evidence and recommendations for catheterisation</td>
<td>18</td>
</tr>
<tr>
<td>3.4.2.5.3 Intravesical drug treatment</td>
<td>18</td>
</tr>
<tr>
<td>3.4.2.5.4 Summary of evidence and recommendations for intravesical drug treatment</td>
<td>19</td>
</tr>
<tr>
<td>3.4.2.5.5 Botulinum toxin injections in the bladder</td>
<td>19</td>
</tr>
<tr>
<td>3.4.2.5.6 Bladder neck and urethral procedures</td>
<td>19</td>
</tr>
<tr>
<td>3.4.2.5.7 Summary of evidence and recommendations for botulinum toxin A injections and bladder neck procedures</td>
<td>19</td>
</tr>
</tbody>
</table>
3.4.3 Surgical treatment
3.4.3.1 Bladder neck and urethral procedures 20
3.4.3.2 Denervation, deafferentation, sacral neuromodulation 21
3.4.3.3 Bladder covering by striated muscle 22
3.4.3.4 Bladder augmentation 22
3.4.3.5 Urinary diversion 22
3.4.3.6 Summary of evidence and recommendations for surgical treatment 23

3.5 Urinary tract infection in neuro-urological patients 23
3.5.1 Epidemiology, aetiology and pathophysiology 23
3.5.2 Diagnostic evaluation 23
3.5.3 Disease management 24
3.5.3.1 Recurrent UTI 24
3.5.3.2 Prevention 24
3.5.4 Summary of evidence and recommendations for the treatment of UTI 24

3.6 Sexual function and fertility 25
3.6.1 Erectile dysfunction 25
3.6.1.1 Phosphodiesterase type 5 inhibitors (PDE5Is) 25
3.6.1.2 Drug therapy other than PDE5Is 25
3.6.1.3 Mechanical devices 25
3.6.1.4 Intracavernous injections and intraurethral application 25
3.6.1.5 Sacral neuromodulation 26
3.6.1.6 Penile prostheses 26
3.6.1.7 Summary of evidence and recommendations for erectile dysfunction 26
3.6.2 Male fertility 26
3.6.2.1 Sperm quality and motility 27
3.6.2.2 Summary of evidence and recommendations for male fertility 27
3.6.3 Female sexuality 27
3.6.4 Female fertility 28
3.6.4.1 Summary of evidence and recommendation for female sexuality and fertility 28

3.7 Follow-up 28
3.7.1 Introduction 28
3.7.2 Summary of evidence and recommendations for follow-up 29

3.8 Conclusions 29

4. REFERENCES 29

5. CONFLICT OF INTEREST 56

6. CITATION INFORMATION 56
1. INTRODUCTION

1.1 Aim and objectives
The European Association of Urology (EAU) Neuro-Urology Guidelines aim to provide information for clinical practitioners on the incidence, definitions, diagnosis, therapy, and follow-up of neuro-urological disorders. These Guidelines reflect the current opinion of experts in this specific pathology and represent a state-of-the-art reference for all clinicians, as of the publication date.

The terminology used and the diagnostic procedures advised throughout these Guidelines follow the recommendations for investigations of the lower urinary tract (LUT) as published by the International Continence Society (ICS) [1-3]. Readers are advised to consult other EAU Guidelines that may address different aspects of the topics discussed in this document.

It must be emphasised that clinical guidelines present the best evidence available to the experts but following guideline recommendations will not necessarily result in the best outcome. Guidelines can never replace clinical expertise when making treatment decisions for individual patients, but rather help to focus decisions - also taking personal values and preferences/individual circumstances of patients into account. Guidelines are not mandates and do not purport to be a legal standard of care.

1.2 Panel composition
The EAU Neuro-Urology Guidelines Panel consists of an international multidisciplinary group of neuro-urological experts. All experts involved in the production of this document have submitted potential conflict of interest statements which can be viewed on the EAU website: http://www.uroweb.org/guideline/neuro-urology/.

1.3 Available publications
A quick reference document, the Pocket Guidelines, is available in print and as an app for iOS and Android devices. These are abridged versions which may require consultation with the full text version. A guideline summary has also been published in European Urology [4]. All are available through the EAU website: http://www.uroweb.org/guideline/neuro-urology/.

1.4 Publication history and summary of changes
1.4.1 Publication history
The EAU Guidelines on Neuro-Urology were first published in 2003. Standard procedure for EAU Guidelines includes an annual assessment of newly published literature in the field to guide future updates. This 2024 Neuro-Urology Guidelines present an update of the 2022 publication.

1.4.2 Summary of changes
All chapters of the 2024 Neuro-Urology Guidelines have been updated, based on the 2023 version of the Guidelines. References have been added throughout the document resulting in various text updates and changes in evidence summaries and recommendations including but not limited to:

- Updates throughout Table 1 and the inclusion of data for Myasthenia gravis.
- A new recommendation for blood pressure and heart rate monitoring in section 3.3.7.4.
- A new paragraph on other drugs used as medical therapy for neuro-urological symptoms in section 3.4.2.3 as well as a new summary of evidence (SOE) and recommendation for mirabegron in section 3.4.2.4.
- Multiple text updates in section 3.4.3. on the various surgical intervention options for SUI in neuro-urological patients.
- A new SOE and recommendation for sacral neuromodulation in section 3.4.3.6.
- A new recommendation against the use of dipstick urine analysis to screen for UTI in neuro-urological patients in section 3.5.4.

1.5 Background
The function of the LUT is mainly storage and voiding of urine, which is regulated by the nervous system that co-ordinates the activity of the urinary bladder and bladder outlet. The part of the nervous system that regulates LUT function is disseminated from the peripheral nerves in the pelvis to highly specialised cortical areas. Any disturbance of the nervous system involved, can result in neuro-urological symptoms. The extent and location of the disturbance will determine the type of LUT dysfunction, which can be symptomatic or asymptomatic. Neuro-urological symptoms can cause a variety of long-term complications; the most significant being deterioration of renal function. Since symptoms and long-term complications do not correlate [5], it is important to identify patients with neuro-urological symptoms, and establish if they have a low or high risk of subsequent
complications. The risk of developing upper urinary tract (UUT) damage and renal failure is much lower in patients with slowly progressive non-traumatic neurological disorders than in those with spinal cord injury or spina bifida [6]. In summary, treatment and intensity of follow-up examinations are based on the type of neuro-urological disorder and the underlying cause.

2. METHODS

2.1 Introduction
For the 2024 Neuro-Urology Guidelines, new and relevant evidence has been identified, collated, and appraised through a structured assessment of the literature. A broad and comprehensive literature search, covering all sections of the Neuro-Urology Guidelines was performed. Databases searched included Medline, EMBASE, and the Cochrane Libraries, covering a time frame between the 1st of May 2021 and 1st May 2023. A total of 1,896 unique records were identified, retrieved, and screened for relevance. A detailed search strategy is available online: http://uroweb.org/guideline/neuro-urology/?type=appendices-publications.

Recommendation within the Guidelines are developed by the panels to prioritise clinically important care decisions. The strength of each recommendation is determined by the balance between desirable and undesirable consequences of alternative management strategies, the quality of the evidence (including certainty of estimates), and the nature and variability of patient values and preferences. This decision process, which can be reviewed in the strength rating forms which accompany each guideline statement, addresses a number of key elements:

1. the overall quality of the evidence which exists for the recommendation [7];
2. the magnitude of the effect (individual or combined effects);
3. the certainty of the results (precision, consistency, heterogeneity and other statistical or study related factors);
4. the balance between desirable and undesirable outcomes;
5. the impact and certainty of patient values and preferences on the intervention.

Strong recommendations typically indicate a high degree of evidence quality and / or a favourable balance of benefit to harm and patient preference. Weak recommendations typically indicate availability of lower quality evidence, and/or equivocal balance between benefit and harm, and uncertainty or variability of patient preference [8].

Additional methodology information and a list of associations endorsing the EAU Guidelines can be found in the online: https://uroweb.org/eau-guidelines/methodology-policies.

2.2 Review
Publications ensuing from panel-lead systematic reviews (SR) have all been peer-reviewed. The 2024 Neuro-Urology Guidelines were subject to peer review prior to publication.

3. THE GUIDELINE

3.1 Epidemiology, aetiology and pathophysiology
3.1.1 Introduction
Neuro-urological symptoms may be caused by a variety of diseases and events affecting the nervous system controlling the LUT. The resulting neuro-urological symptoms depend predominantly on the location and the extent of the neurological lesion. There are no exact figures on the overall prevalence of neuro-urological disorders in the general population, but data are available on the prevalence of the underlying conditions and the relative risk of these for the development of neuro-urological symptoms. It is important to note that the majority of the data shows a very wide range of prevalence/incidence. This reflects the variability in the cohort (e.g., early or late-stage disease) and the frequently small sample sizes, resulting in a low level of evidence in most published data (summarised in Table 1).
## Table 1: Epidemiology of Neuro-Urological Disorders

<table>
<thead>
<tr>
<th>Neurological Disease</th>
<th>Frequency in General Population</th>
<th>Type and Frequency of Neuro-Urological Symptoms</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cerebrovascular accident (Strokes)</td>
<td>450 cases/100,000/yr (Europe) [9], 10% of cardiovascular mortality.</td>
<td>Nocturia - overactive bladder (OAB) - urgency urinary incontinence (UUI) - neurogenic detrusor overactivity (NDO), other patterns less frequent [10]. 57-83% of neuro-urological symptoms at one month post-stroke, 71-80% spontaneous recovery at six months [11]. Persistence of urinary incontinence (UI) correlates with poor prognosis [12].</td>
</tr>
<tr>
<td>Dementias: Alzheimer’s disease (80%), Vascular (10%), Other (10%).</td>
<td>6.4% of adults &gt; 65 yrs [13].</td>
<td>OAB - UUI – NDO, 25% of incontinence in Alzheimer’s disease, &gt; 25% in other dementias: Lewy body, NPH, Binswanger, Nasu-Hakola, Pick Disease [14]. Incontinence three times more frequent in geriatric patients with dementia than without [15].</td>
</tr>
<tr>
<td>Parkinsonian syndrome (PS)</td>
<td>Second most prevalent neurodegenerative disease after Alzheimer’s disease. Rising prevalence of IPD with age [16].</td>
<td>LUTS affect 50% at onset, with urgency and nocturia being the most common. Patients with LUTS at presentation have worse disease progression in Parkinson’s disease [17]. LUTS prevalence data depend on gender, age, and Hoehn and Yahr stage [18].</td>
</tr>
<tr>
<td>Brain tumours</td>
<td>26.8/100,000/yr in adults (&gt; 19 yrs), (17.9 benign, 8.9 malignant) [23].</td>
<td>Incontinence occurs mainly in frontal location (part of frontal syndrome or isolated in frontal location) [24].</td>
</tr>
<tr>
<td>Cerebral palsy</td>
<td>Cerebral palsy: 3.1-3.6/1,000 in children aged 8 yrs [25].</td>
<td>32-46% of patients with cerebral palsy suffer from UI, with 85% of patients having abnormal urodynamic studies (NDO most common 59%). Upper tract deterioration is rare (2.5%) [26, 27].</td>
</tr>
<tr>
<td>Traumatic brain injury</td>
<td>235/100,000/yr [28].</td>
<td>44% storage dysfunction, 38% voiding dysfunction, 60% urodynamic abnormalities [29].</td>
</tr>
<tr>
<td>Normal pressure hydrocephalus</td>
<td>0.5% of the population &gt; 60, up to 2.9% of those &gt; 65 [30].</td>
<td>Classic triad of gait and cognitive disturbance along with neurogenic lower urinary tract dysfunction (NLUTD). The latter is mainly related to NDO and affects 76-83% of patients [30].</td>
</tr>
</tbody>
</table>
Lesions and diseases between caudal brainstem and sacral spinal cord

<table>
<thead>
<tr>
<th>Lesion/Disease</th>
<th>Prevalence/Incidence/Features</th>
<th>Outcomes/Complications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Spinal cord injury (SCI)</td>
<td>Prevalence of traumatic SCI in developed countries ranges from 280 to 906/million [31].</td>
<td>NDO and detrusor sphincter dyssynergia (DSD) (up to 95%) and detrusor underactivity (DU) (up to 83%) depending on the level of the lesion [32].</td>
</tr>
<tr>
<td>Spina bifida (SB)</td>
<td>Spina bifida 3-4/10,000 Lumbar and lumbosacral form are the most common (60%) [33].</td>
<td>Bladder function is impaired in up to 96% of SB patients [34]. Over 50% of patients are incontinent [35]. Patients with open and closed defects can have equally severe NLUTD [36].</td>
</tr>
<tr>
<td>Hereditary spastic paraplegia (HSP)</td>
<td>Prevalence 1.3-9/100,000 [37].</td>
<td>LUTS in about 75%, mainly urgency and voiding dysfunction NDO in 81% (of whom 76% with DSD) [37]</td>
</tr>
</tbody>
</table>

Lesions and diseases of the peripheral nervous system

| Peripheral neuropathy                                                         | Lumbar spine Degenerative disease Disk prolapse Lumbar canal stenosis Male (5%) and female (3%) > 35 yr. have had a lumbo sacral episode related to disc prolapse. Incidence: approx. 5/100,000/yr More common in females > 45 yr. 26% difficulty to void and acontractile detrusor [38]. Detrusor underactivity (up to 83%) [32]. Tarlov cysts: early sensation of filling (70%), NDO (33%), and stress urinary incontinence (SUI) (33%) [39]. |
|--------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Other causes of peripheral neuropathy causing neuro-urological symptoms:         | Worldwide, prevalence of pharmacologically treated diabetes 8.3% [41].                                                                                                                                                                                  | OAB +/- UUI [42]. Hypersensitivity and DU at later phase [42].                                                                                                                                                                                        |
| Myasthenia gravis                                                              | Prevalence 20/100,000 [43]                                                                                                                                                                                                                        | Increased daytime frequency, nocturia, incontinence [43]                                                                                                                                                                                                  |
| Disseminated central diseases                                                   | Prevalence: 83/100,000 in Europe [44].                                                                                                                                                                                                           | 10% of MS patients present with voiding dysfunction at disease onset, 75% of patients will develop it after 10 yrs of MS [45]. NDO: 65% [45], 43% [46]. DSD: 35% [45, 46]. DU: 25% [45]. |
3.2 Classification systems

3.2.1 Introduction

Relevant definitions can be found in the general ICS standardisation reports [2, 3, 47, 48]. Supplementary online Tables S1 and S2 list the definitions from these references, partly adapted, and other definitions considered useful for clinical practice: https://uroweb.org/guideline/neuro-urology/?type=appendices-publications. A classification system that also includes UUT dysfunction in neuro-urological patients has also been described [48].

3.3 Diagnostic evaluation

3.3.1 Introduction

The normal physiological function of the LUT depends on an intricate interplay between the sensory and motor nervous systems. When diagnosing neuro-urological symptoms, the aim is to describe the type of dysfunction involved. A thorough medical history, physical examination and bladder diary are mandatory before any additional diagnostic investigations can be planned. Results of the initial evaluation are used to decide the patient’s long-term treatment and follow-up.

3.3.2 Classification systems

The pattern of LUT dysfunction following neurological disease is determined by the site and nature of the lesion. A very simple classification system for use in daily clinical practice to decide on the appropriate therapeutic approach is provided in Figure 1 [6].

Figure 1: Patterns of lower urinary tract dysfunction following neurological disease

The pattern of LUT dysfunction following neurological disease is determined by the site and nature of the lesion. Panel (A) denotes the region above the pons, panel (B) the region between the pons and the sacral cord and panel (C) the sacral cord and infrasacral region. Figures on the right show the expected dysfunctional states of the detrusor-sphincter system. Figure adapted from Panicker et al., [6] with permission from Elsevier. PVR = post-void residual.
3.3.3 **Timing of diagnosis and treatment**

Early diagnosis and treatment are essential in both congenital and acquired neuro-urological disorders. This helps to prevent irreversible changes within the LUT, even in the presence of normal reflexes [49]. Furthermore, urological symptoms can be the presenting feature of neurological pathology [50, 51]. Early intervention can prevent irreversible deterioration of the LUT and UUT [51]. Long term follow-up (life-long) is mandatory to assess risk of UUT damage and renal failure [52, 53].

3.3.4 **Patient history**

History taking should include past and present symptoms and disorders (Table 4). It is the cornerstone of evaluation, as the answers will aid selection of diagnostic investigations and treatment options.

- In non-traumatic neuro-urological patients with an insidious onset, a detailed history may find that the condition started in childhood or adolescence [54].
- Urinary history consists of symptoms associated with both urine storage and voiding.
- Bowel history is important because patients with neuro-urological symptoms may also have related neurogenic bowel dysfunction [55].
- Sexual function may be impaired because of the neuro-urological condition [56].
- Special attention should be paid to possible warning signs and symptoms (e.g., pain, infection, haematuria, and fever) requiring further investigation.
- Patients with SCI usually find it difficult to report urinary tract infection (UTI)-related symptoms accurately [57, 58].
- The presence of urinary, bowel and sexual symptoms without neurological symptoms could be suggestive of an underlying neurological disease or condition.
- The severity of lesion after acute SCI does not predict the presence or absence of unfavourable urodynamic parameters [49].

### Table 4: History taking in patients with suspected neuro-urological disorder

<table>
<thead>
<tr>
<th>Past history</th>
<th>Present history</th>
</tr>
</thead>
<tbody>
<tr>
<td>Childhood through to adolescence and into adulthood</td>
<td>Present medication</td>
</tr>
<tr>
<td>Hereditary or familial risk factors</td>
<td></td>
</tr>
<tr>
<td>Specific female: menarche (age); this may suggest a metabolic disorder</td>
<td>Lifestyle (smoking, alcohol and drugs); may influence urinary, sexual and bowel function</td>
</tr>
<tr>
<td>Obstetric history</td>
<td>Quality of life</td>
</tr>
<tr>
<td>History of diabetes</td>
<td>Specific urinary history</td>
</tr>
<tr>
<td>Diseases, e.g., multiple sclerosis, parkinsonism, encephalitis, syphilis</td>
<td>Onset of urological history</td>
</tr>
<tr>
<td>Accidents and operations, especially those involving the spine and central nervous system</td>
<td>Relief after voiding; to detect the extent of a neurological lesion in the absence of obstructive uropathy</td>
</tr>
<tr>
<td></td>
<td>Bladder sensation (painful, abnormal, absent or increased)</td>
</tr>
<tr>
<td></td>
<td>Initiation of micturition (normal, precipitate, reflex, strain, Credé)</td>
</tr>
<tr>
<td></td>
<td>Interruption of micturition (normal, paradoxical, passive)</td>
</tr>
<tr>
<td></td>
<td>Enuresis</td>
</tr>
<tr>
<td></td>
<td>Mode and type of voiding (catheterisation)</td>
</tr>
<tr>
<td></td>
<td>Frequency, voided volume, stress/urgency/mixed urinary incontinence, urgency episodes</td>
</tr>
</tbody>
</table>
### Sexual history
- Genital or sexual dysfunction symptoms
- Sensation in genital area (absent, increased, abnormal, pain)
- Specific male: libido, erection, (lack of) orgasm, ejaculation
- Specific female: libido, dyspareunia, (lack of) orgasm

### Bowel history
- Type of bowel program
- Frequency and faecal incontinence
- Desire to defecate
- Defecation pattern
- Rectal sensation
- Initiation of defecation (digital stimulation, enema, suppositories)

### Neurological history
- Acquired or congenital neurological condition
- Mental status and comprehension
- Neurological symptoms (somatic and sensory), with onset, evolution, and any treatment
- Spasticity or autonomic dysreflexia (AD) (especially in lesions at or above level Th 6)
- Mobility and hand function

#### 3.3.4.1 Bladder diaries
Bladder diaries are considered a valuable diagnostic tool for the initial assessment of neurogenic LUT dysfunction. They provide data on the number of voids (spontaneous or intermittent catheter), voided volume, stress/urgency/mixed urinary incontinence episodes and contribute to the interpretation of urodynamic testing. Preferably, bladder diaries should be completed for three consecutive days [59].

#### 3.3.5 Patient quality of life questionnaires
Quality of life (QoL) is an essential aspect of the overall management of neuro-urological patients, for example when evaluating treatment related changes on a patient’s QoL [60]. The type of bladder management has been shown to affect health-related QoL (HRQoL) mainly in patients with SCI [61, 62] and MS [63], as does the presence or absence of urinary, sexual and faecal incontinence [64]. Other research has also highlighted the importance of urological treatment and its impact on the urodynamic functionality of the neuro-urological patient in determining patient QoL [65].

In recent years a proliferation in the number of questionnaires to evaluate symptoms and QoL has been seen. Condition-specific questionnaires can be used to assess symptom severity and the impact of symptoms on QoL. A patient’s overall QoL can be assessed using generic questionnaires. It is important that the questionnaire of choice has been validated in the neuro-urological population, and that it is available in the language that it is to be used in.

#### 3.3.5.1 Available Questionnaires
Three condition-specific questionnaires for urinary or bowel dysfunction and QoL have been developed specifically for adult neuro-urological patients [63]. In MS and SCI patients the Qualiveen, also available in a short version, is validated and translated into various languages [66, 67]. Although several objective and subjective tools have been used to assess the influence of neurogenic lower urinary tract dysfunctions (N-LUTD) on QoL in SCI, the Quality life index-SCI and Qualiveen are the only validated condition-specific outcomes that have shown consistent sensitivity [68]. The Neurogenic Bladder Symptom Score (NBSS) and its short version has been validated in neurological patients to measure urinary symptoms and their consequences [69-71]. The QoL scoring tool related to Bowel Management (QoL-BM) [72] can be used to assess bowel dysfunction in MS and SCI patients. A new tool has recently been developed to understand the reasons for poor compliance in long-term management of neurogenic patients. [73, 74]. A variety of patient-reported outcome measures (PROMs) are available to evaluate sexual function in neuro-urological patients. However, only the Multiple Sclerosis Intimacy and Sexuality Questionnaire-15 (MSISQ-15) and -19 is supported by evidence [75-77].
In addition, several validated questionnaires that evaluate QoL and assess urinary symptoms as a subscale or question in neuro-urological patients have been identified [78] (Table 5). The condition-specific Incontinence-Quality of Life (I-QoL) questionnaire which was initially developed for the non-neurological population has now also been validated for neuro-urological patients [79].

A patient’s overall QoL can be assessed by generic HRQoL questionnaires, the most commonly used being the I-QOL, King’s Health Questionnaire (KHQ), or the Short Form 36-item and 12-item Health Survey Questionnaires (SF-36, SF-12) [80]. In addition, the quality-adjusted life year (QALY), quantifies outcomes, by weighing years of life spent in a specified health state, adjusted by a factor representing the value placed by society or patients on their specific health state [81].

No evidence was found for which validated questionnaires are the most appropriate for use, since no quality criteria for validated questionnaires have been assessed [80].

Table 5: Patient questionnaires

<table>
<thead>
<tr>
<th>Questionnaire</th>
<th>Underlying neurological disorder</th>
<th>Bladder</th>
<th>Bowel</th>
<th>Sexual function</th>
</tr>
</thead>
<tbody>
<tr>
<td>FAMS [82]</td>
<td>MS</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>FILMS [83]</td>
<td>MS</td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>HAQUAMS [84]</td>
<td>MS, SCI</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>I-QOL [79]</td>
<td>MS, SCI</td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>LUTS-TCA [73]</td>
<td>MS, SCI, Parkinson</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MDS [85]</td>
<td>MS</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MSISO-15 / MSISO-19 [75, 76]</td>
<td>MS, SCI</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>MSQI [86]</td>
<td>MS</td>
<td>X</td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>MSQoL-S4 [87]</td>
<td>MS</td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>MSWDQ [88]</td>
<td>MS</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NBSS [69, 71]</td>
<td>MS, SCI, SB, Cerebral Palsy</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NBSS-SF [70]</td>
<td>MS, SCI, SB</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>QoL-BM [72]</td>
<td>SCI</td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Qualiveen/SF-Qualiveen [67, 89]</td>
<td>MS, SCI</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>RAYS [90]</td>
<td>MS</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>RHSCIR [91]</td>
<td>SCI</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>USQNB [74]</td>
<td>SCI</td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
</tbody>
</table>

3.3.6 Physical examination and additional tests

In addition to a detailed patient history, attention should be paid to possible physical and intellectual disabilities with respect to the planned investigations [92, 93]. Neuro-urological status should be described as completely as possible (Figure 2) [6]. Patients with a high spinal cord lesion or supraspinal neurological lesions may suffer from a significant drop in blood pressure when moved into a sitting or standing position. All sensations and reflexes in the urogenital area must be tested [6]. Furthermore, detailed testing of the anal sphincter and pelvic floor functions must be performed (Figure 2) [6, 94]. It is essential to have this clinical information to reliably interpret later diagnostic investigations (Table 6).

Additionally, urinalysis, blood chemistry, ultrasonography, post-void residual when indicated, incontinence quantification and free uroflowmetry, should be performed as part of the routine assessment of neuro-urological patients [6, 95].

3.3.6.1 Autonomic dysreflexia

Autonomic dysreflexia (AD) is a sudden and exaggerated autonomic response to various stimuli generally manifests in patients with SCI or spinal dysfunction at or above level Th 6. It is defined by an increase in systolic blood pressure > 20 mmHg from baseline and it is usually accompanied by a severe headache, blurred vision, feeling of anxiety, heart rate changes, as well as above the lesion, perspiration, piloerection, warm skin and flushing and below the lesion, pallor, cold skin, and sweating in the lower part of the body [96, 97]. Autonomic dysreflexia can have life-threatening consequences if not managed adequately. The stimulus can be distended
bladder or bowel (e.g., iatrogenic stimuli during cystoscopy or urodynamics) [98], but it can also be secondary to any noxious stimulus (e.g., infected toenail or pressure sore) or after sexual stimulation.

**Figure 2: Lumbosacral dermatomes, cutaneous nerves, and reflexes**

The physical examination includes testing sensations and reflexes mediated through the lower spinal cord. Abnormal findings would suggest a lesion affecting the lumbosacral segments; mapping out distinct areas of sensory impairment helps to further localise the site of the lesion. Distribution of dermatomes (areas of skin mainly supplied by a single spinal nerve) and cutaneous nerves over the perianal region and back of the upper thigh (A), the perineum [99] (B), male external genitalia [100] (C) and root values of lower spinal cord reflexes (D). Figure adapted from Panicker et al., [6] with parts A-C adapted from Standring [101], both with permission from Elsevier.

**Table 6: Neuro-urological items to be specified**

<table>
<thead>
<tr>
<th>Sensation S2-S5 (both sides)</th>
<th>Presence (increased/normal/reduced/absent)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Type (light touch/pin prick)</td>
</tr>
<tr>
<td></td>
<td>Affected dermatomes</td>
</tr>
<tr>
<td>Reflexes (increased/normal/reduced/absent)</td>
<td></td>
</tr>
<tr>
<td>Bulbocavernous reflex</td>
<td></td>
</tr>
<tr>
<td>Perianal/anal reflex</td>
<td></td>
</tr>
<tr>
<td>Knee and ankle reflexes</td>
<td></td>
</tr>
<tr>
<td>Plantar responses (Babinski)</td>
<td></td>
</tr>
<tr>
<td>Anal sphincter tone</td>
<td>Presence (increased/normal/reduced/absent)</td>
</tr>
<tr>
<td>Voluntary contractions of anal sphincter and pelvic muscles (increased/normal/reduced/absent)</td>
<td></td>
</tr>
</tbody>
</table>
General urogenital assessment

<table>
<thead>
<tr>
<th>General urogenital assessment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prostate palpation</td>
</tr>
<tr>
<td>Skin lesions</td>
</tr>
<tr>
<td>Size and presence of penis</td>
</tr>
<tr>
<td>Descensus (prolapse) of pelvic organs</td>
</tr>
</tbody>
</table>

3.3.6.2 Summary of evidence and recommendations for history taking and physical examination

<table>
<thead>
<tr>
<th>Summary of evidence</th>
<th>LE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Early diagnosis and treatment are essential in both congenital and acquired neuro-urological disorders to prevent irreversible changes within the LUT.</td>
<td>4</td>
</tr>
<tr>
<td>An extensive general history is the basis of evaluation focusing on past and present symptoms including urinary, sexual, bowel and neurological function.</td>
<td>4</td>
</tr>
<tr>
<td>Assessment of present and expected future QoL is an essential aspect of the overall management of neuro-urological patients and is important to evaluate the effect of any therapy.</td>
<td>2a</td>
</tr>
<tr>
<td>Quality of life assessment should be completed with validated QoL questionnaires for neuro-urological patients.</td>
<td>1a</td>
</tr>
<tr>
<td>Bladder diaries provide data on the number of voids, voided volume, urinary incontinence, and urgency episodes.</td>
<td>3</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Strength rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>Take an extensive general history, concentrating on past and present symptoms.</td>
<td>Strong</td>
</tr>
<tr>
<td>Take a specific history for each of the four mentioned functions - urinary, bowel, sexual and neurological.</td>
<td>Strong</td>
</tr>
<tr>
<td>Pay special attention to the possible existence of alarm symptoms/signs (e.g. pain, infection, haematuria, fever) that warrant further specific diagnosis.</td>
<td>Strong</td>
</tr>
<tr>
<td>Assess quality of life when evaluating and treating neuro-urological patients.</td>
<td>Strong</td>
</tr>
<tr>
<td>Use available validated tools for urinary and bowel symptoms in neuro-urological patients.</td>
<td>Strong</td>
</tr>
<tr>
<td>Use MSISQ-15 or MSISQ-19 to evaluate sexual function in multiple sclerosis patients.</td>
<td>Strong</td>
</tr>
<tr>
<td>Acknowledge individual patient disabilities when planning further investigations.</td>
<td>Strong</td>
</tr>
<tr>
<td>Describe the neurological status as completely as possible, sensations and reflexes in the urogenital area must all be tested.</td>
<td>Strong</td>
</tr>
<tr>
<td>Test the anal sphincter and pelvic floor functions.</td>
<td>Strong</td>
</tr>
<tr>
<td>Perform urinalysis, blood chemistry, bladder diary, post-void residual, incontinence quantification and urinary tract imaging as initial and routinary evaluation.</td>
<td>Strong</td>
</tr>
</tbody>
</table>

MSISQ 15/19 = Multiple Sclerosis Intimacy and Sexuality Questionnaire 15/19 question version.

3.3.7 Urodynamics

3.3.7.1 Introduction

Urodynamic investigation is the only method that can objectively assess the function and dysfunction of the LUT. In neuro-urological patients, invasive urodynamic investigation is even more challenging than in general patients. Any technical source of artefacts must be critically considered. It is essential to maintain the quality of the urodynamic recording and its interpretation [1]. Same session repeat urodynamic investigations are crucial in clinical decision making, since repeat measurements may yield completely different results [102].

In patients at risk of AD, blood pressure (BP) and heartrate monitoring during the urodynamic study and other invasive procedures is mandatory [97, 103]. The rectal ampulla should be empty of stool before the start of the investigation. All urodynamic findings must be reported in detail and performed, according to the ICS technical recommendations and standards [1, 104].

In patients with SCI, first urodynamic investigation should take place within 3 months after SCI to facilitate early diagnosis of unfavourable urodynamic parameters and timely treatment [105] but there is need for further research regarding the urodynamic follow-up schedule during the first year after SCI [106].
3.3.7.2 Urodynamic tests

*Free uroflowmetry and assessment of residual urine:* It is recommended prior to planning any invasive urodynamics that patients are able to void in the usual position. For reliable information, it should be repeated at least two to three times [1]. Possible pathological findings include a low flow rate, low voided volume, intermittent flow, hesitancy and PVR.

*Filling cystometry:* This test is the only method for quantifying the patient’s filling function. The status of LUT function must be documented during the filling phase. However, this technique has limited use as a solitary procedure. It is much more effective combined with bladder pressure measurement during micturition and is even more effective in video-urodynamics.

The bladder should be empty at the start of filling. A physiological filling rate should be used with body-warm saline. Possible pathological findings include neurogenic detrusor overactivity (NDO), low bladder compliance, abnormal bladder sensations, low cystometric capacity and urinary incontinence.

*Detrusor leak point pressure* [107]: Appears to have no use as a diagnostic tool. Some positive findings have been reported [52, 108, 109], but sensitivity is too low to estimate the risk to the UUT or for secondary bladder damage [110, 111].

*Pressure flow study (or voiding cystometry):* Reflects the coordination between detrusor and urethra or pelvic floor during the voiding phase. It is even more effective if combined with filling cystometry and video-urodynamics. Possible pathological findings include detrusor underactivity, acontractility, bladder outlet obstruction (BOO), DSD, a high urethral resistance, and residual urine.

Most types of obstruction caused by neuro-urological disorders are due to DSD [112, 113], non-relaxing urethra, and/or non-relaxing bladder neck [114, 115]. Pressure-flow analysis mainly assesses the amount of mechanical obstruction caused by the urethra's inherent mechanical and anatomical properties.

*Electromyography (EMG):* Reflects the activity of the external urethral sphincter, the peri-urethral striated musculature, the anal sphincter, and the striated pelvic floor muscles. Correct interpretation may be difficult due to artefacts introduced by other equipment. In the urodynamic setting, an EMG is useful as a gross indication of the patient's ability to control the pelvic floor. Possible pathological findings include inadequate recruitment upon specific stimuli (e.g. bladder filling, involuntary detrusor contractions, onset of voiding, coughing, Valsalva manoeuvre) suggesting a diagnosis of DSD [116].

*Urethral pressure measurement:* Has a very limited role in neuro-urological disorders. There is no consensus on parameters indicating pathological findings [117].

*Video-urodynamics:* Is the combination of filling cystometry and pressure flow studies with imaging. It is the optimum procedure for urodynamic investigation in neuro-urological disorders [5]. Possible pathological findings include all those described in the filling cystometry and the pressure flow study sections, and any morphological pathology of the LUT and reflux to the UUT [118].

*Ambulatory urodynamics:* This is the functional investigation of the urinary tract, which predominantly uses the natural filling of the urinary tract to reproduce the patient’s normal activity. Although this type of study might be considered when conventional urodynamics does not reproduce the patient’s symptoms, its role in the neuro-urological patient still needs to be determined [119, 120].

*Triggered tests during urodynamics:* Lower urinary tract function can be provoked by coughing, triggered voiding, or anal stretch. Fast-filling cystometry with cooled saline (the ‘ice water test’) was initially described to discriminate between upper and lower motor neuron lesions [121, 122]. Patients with upper motor neuron lesions develop a detrusor contraction if the detrusor is intact, while patients with lower motor neuron lesions do not. However, the test does not seem to be fully discriminative since also non neurological and lower motor SCI have shown positive test [123, 124].

Previously, a positive bethanechol test [125] (detrusor contraction > 25 cm H2O) was thought to indicate detrusor denervation hypersensitivity and the muscular integrity of an acontractile detrusor. However, in practice, the test has given equivocal results. A variation of this method was reported using intravesical electromotive administration of the bethanechol [126], but there was no published follow-up. Currently, there is no indication for this test.
3.3.7.3  Specialist uro-neurophysiological tests

The following tests are advised as part of the neurological work-up [127]:

- electromyography (in a neurophysiological setting) of pelvic floor muscles, urethral sphincter and/or anal sphincter;
- nerve conduction studies of pudendal nerve;
- reflex latency measurements of bulbocavernosus and anal reflex arcs;
- evoked responses from clitoris or glans penis;
- sensory testing on bladder and urethra.

Other elective tests, for specific conditions, may become obvious during the work-up and urodynamic investigations.

3.3.7.4  Summary of evidence and recommendations for urodynamics and uro-neurophysiological tests

<table>
<thead>
<tr>
<th>Summary of evidence</th>
<th>LE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Urodynamic investigation is the only method that can objectively assess the (dys-)function of the LUT.</td>
<td>2a</td>
</tr>
<tr>
<td>Video-urodynamics is the optimum procedure for urodynamic investigation in neuro-urological disorders.</td>
<td>4</td>
</tr>
<tr>
<td>Specific uro-neurophysiological tests are elective procedures and should only be carried out in specialised settings.</td>
<td>4</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Strength rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>Perform a urodynamic investigation to detect and specify lower urinary tract (dys-)function, use same session repeat measurement as it is crucial in clinical decision making.</td>
<td>Strong</td>
</tr>
<tr>
<td>Non-invasive testing is mandatory before invasive urodynamics is planned.</td>
<td>Strong</td>
</tr>
<tr>
<td>Use video-urodynamics for invasive urodynamics in neuro-urological patients. If this is not available, then perform a filling cystometry continuing into a pressure flow study.</td>
<td>Strong</td>
</tr>
<tr>
<td>Use a physiological filling rate and body-warm saline.</td>
<td>Strong</td>
</tr>
<tr>
<td>Perform blood pressure and heart rate monitoring during urodynamic investigation and other invasive procedures in patients at risk for autonomic dysreflexia.</td>
<td>Strong</td>
</tr>
</tbody>
</table>

3.3.8  Renal function

In many patients with neuro-urological disorders, the UUT is at risk, particularly in patients who develop high detrusor pressure during the filling phase. Although effective treatment can reduce this risk, there is still a relatively high incidence of renal morbidity [128, 129]. Patients with SCI or SB have a higher risk of developing renal failure compared with patients with slowly progressive non-traumatic neurological disorders, such as MS and Parkinson's disease (PD) [130].

Caregivers must be informed of this risk and instructed to watch carefully for any signs or symptoms of a possible deterioration in the patient's renal function. In patients with poor muscle mass cystatin C based glomerular filtration rate (GFR) seems to be more accurate in detecting chronic kidney disease than serum creatinine estimated GFR [131]. There are no high-level evidence publications available which show the optimal management to preserve renal function in these patients [132].

3.4  Disease management

3.4.1  Introduction

The primary aims for treatment of neuro-urological symptoms, and their priorities, are [129, 130]:

- protection of the UUT;
- achievement (or maintenance) of urinary continence;
- restoration of LUT function;
- improvement of the patient’s QoL.

Further considerations are the patient’s disability, cognition, social support, caregiver support, cost-effectiveness, technical complexity and possible complications [134].
Historically, renal failure was the main mortality factor in SCI patients who survived the trauma [135, 136]. Keeping the detrusor pressure during both the filling and voiding phases within safe limits significantly reduces the mortality from urological causes in these patients [137-139] and has consequently become the top priority in the treatment of patients with neuro-urological symptoms [133, 134].

In patients with high detrusor pressure during the filling phase (NDO, low bladder compliance), treatment is aimed primarily at conversion of an overactive, high-pressure bladder into a low-pressure reservoir despite the resulting residual urine [133]. Reduction of the detrusor pressure contributes to urinary continence, and consequently to social rehabilitation and QoL. It is also critical for preventing UTIs [140, 141]. However, complete continence cannot always be obtained.

3.4.2 Non-invasive conservative treatment

3.4.2.1 Assisted bladder emptying - Credé manoeuvre, Valsalva manoeuvre, triggered reflex voiding

Incomplete bladder emptying is a serious risk factor for UTI, high intravesical pressure and incontinence. Methods to improve the voiding process should therefore be practiced.

Bladder expression: The downwards movement of the lower abdomen by suprapubic compression (Credé) or by abdominal straining (Valsalva) leads to an increase in intravesical pressure, and generally also causes a reflex sphincter contraction [142, 143]. The latter may increase bladder outlet resistance and lead to inefficient emptying. The high pressures created during these procedures are hazardous for the urinary tract [144, 145]. Therefore, their use should be discouraged unless urodynamics show that the intravesical pressure remains within safe limits [134].

Long-term complications are unavoidable for both methods of bladder emptying [143]. The already weak pelvic floor function may be further impaired, thus introducing or exacerbating already existing SUI [145].

Triggered reflex voiding: Stimulation of the sacral or lumbar dermatomes in patients with a upper motor neuron lesion can elicit a reflex detrusor contraction [145]. The risk of high pressure voiding is present and interventions to decrease outlet resistance may be necessary [146]. Triggering can induce AD, especially in patients with high level SCI (at or above Th 6) [147]. All assisted bladder emptying techniques require low outlet resistance. Even then, high detrusor pressures may still be present. Hence, patients need dedicated education and close urodynamic and urological surveillance [145, 148, 149].

Note: In the literature, including some of the references cited here, the concept "reflex voiding" is sometimes used to cover all three assisted voiding techniques described in this section.

External appliances: Social continence may be achieved by collecting urine during incontinence, for instance using pads. Condom catheters with urine collection devices are a practical method for men [134]. The penile clamp is absolutely contraindicated in case of NDO or low bladder compliance due to the risk of developing high intravesical pressure and pressure sores/necrosis in cases of altered/absent sensations.

3.4.2.2 Neuro-urological rehabilitation

3.4.2.2.1 Bladder rehabilitation including electrical stimulation

The term bladder rehabilitation summarises treatment options that aim to re-establish bladder function in patients with neuro-urological symptoms. Strong contraction of the urethral sphincter and/or pelvic floor, as well as anal dilatation, manipulation of the genital region, and physical activity inhibit micturition in a reflex manner [134, 150]. The first mechanism is affected by activation of efferent nerve fibres, and the latter ones are produced by activation of afferent fibres [110]. Electrical stimulation of the pudendal nerve afferents, strongly inhibits the micturition reflex and detrusor contraction [151]. This stimulation might then support the restoration of the balance between excitatory and inhibitory inputs at the spinal or supraspinal level [134, 152]. Evidence for bladder rehabilitation using electrical stimulation in neurological patients is mainly based on small non-comparative studies with a high risk of bias.

Behavioural therapy and bladder training: In patients with PD, behavioural therapy and bladder training may be considered based on randomised controlled trials (RCTs) with very limited number of patients [153, 154].

Pelvic floor muscle training (PFMT): In patients with MS and stroke, PFMT may have positive effects on LUTS, daytime urinary frequency and urinary incontinence but the evidence is still limited [155, 156].
Peripheral temporary electrostimulation: Tibial nerve stimulation and transcutaneous electrical nerve stimulation (TENS) might be effective and safe for treating neurogenic LUT dysfunction, but more reliable evidence from well-designed RCTs is required to reach definitive conclusions [152, 157, 158]. In post-stroke patients TENS has been shown to effectively improve urodynamic and bladder diary findings as well as QoL [159-161]. In an RCT, transcutaneous tibial nerve home stimulation has proven to significantly improve bladder diary parameters in patients with MS as well as in women with PD [162, 163]. In acute SCI, TENS is able to achieve bladder neuromodulation via modulation of the autonomous nervous system functions [164]. Greater volumes until full sensation, less detrusor-sphincter dyssynergia and an increased bladder capacity can be found when compared to sham-treated patients [165]. A SR on dorsal genital nerve stimulation showed higher relative and absolute bladder capacities and inhibition of detrusor hyperactivity in SCI people, although these therapeutic effects may be dependent on the current, amplitude and longer periods of stimulation [166].

Interferential medium frequency current electrical stimulation for SCI patients with American spinal cord injury association impairment scale (AIS) levels B, C and D demonstrated a significant decrease in PVR and volume of urine leakage between catheterisation [167]. Neuromuscular electrical stimulation applied in the sacral area has also improved the performance in symptoms scores in highly selected patients with UI after stroke [160]; however, new RCTs with more patients and longer follow-up are required.

Peripheral temporary electrostimulation combined with pelvic floor muscle training and biofeedback: In MS patients, combining active neuromuscular electrical stimulation with Pelvic Floor Muscle Training (PFMT) and EMG biofeedback can achieve a substantial reduction of neuro-urological symptoms [168, 169]. This treatment combination seems to be more effective than either therapy alone [170, 171]. However, the combination of intravaginal electrostimulation and PFMT was not superior to PFMT alone in reducing UI in women with incomplete SCI [172].

Intravesical electrostimulation: Intravesical electrostimulation can increase bladder capacity and improve bladder filling sensation in patients with incomplete SCI or myelomeningocele (MMC) [173]. In patients with neurogenic detrusor underactivity, intravesical electrostimulation may also improve voiding and reduce residual volume [174, 175].

Repetitive transcranial magnetic stimulation: Although improvement of neuro-urological symptoms has been described in PD, SCI and MS patients, this technique is still under investigation [176]. The role of cortical as well as sacral magnetic stimulation in MS patients with underactive bladder needs to be better defined [177].

Summary: To date, bladder rehabilitation techniques are mainly based on electrical or magnetic stimulation; however, there is a lack of well-designed studies.

3.4.2.3 Drug treatment
A single, optimal, medical therapy for neuro-urological symptoms is not always available. Commonly, a combination of different therapies (e.g. intermittent catheterisation and antimuscarinic drugs) is advised to prevent urinary tract damage and improve long-term outcomes, particularly in patients with a suprasacral SCI or MS [145, 178-180]. Drug treatments are categorised depending on their mechanism of action and focus on storage or voiding symptoms.

3.4.2.3.1 Drugs for storage symptoms
Antimuscarinic drugs: are the first-line choice for treating NDO, increasing bladder capacity and reducing episodes of UI secondary to NDO by the inhibition of parasympathetic pathways [134, 181-187]. Antimuscarinic drugs have been used for many years to treat patients with NDO [185, 186, 188], and the responses of individual patients to antimuscarinic treatment are variable. Despite a meta-analysis confirming the clinical and urodynamic efficacy of antimuscarinic therapy compared to placebo in adult NDO, a more recent integrative review has indicated that the information provided is still too limited for clinicians to be able to match trial data to the needs of individual patients with SCI, mainly due to the lack of use of standardised clinical evaluation tools such as the American Spinal Injury Association bladder diary and validated symptoms score [186, 189].

Higher doses or a combination of antimuscarinic agents may be an option to maximise outcomes in neurological patients [182, 183, 190-193]. However, these drugs have a high incidence of adverse events, which may lead to early discontinuation of therapy. Despite this, NDO patients have generally shown better treatment adherence compared to idiopathic DO patients [194].
Choice of antimuscarinic agent: Oxybutynin [134, 182, 183, 185, 186, 195], trospium [186, 192, 196], tolterodine [197] and propiverine [186, 198] are established, effective and well-tolerated treatments even in long-term use [185, 186, 199, 200]. Darifenacin [201, 202] and solifenacin [203] have been evaluated in NDO secondary to SCI and MS [186, 201-203] with results similar to other antimuscarinic drugs. A pilot study using solifenacin in NDO due to PD showed an improvement in UI [204]. Fesoterodine, an active metabolite of tolterodine, has also been introduced; improving urodynamic variables in SCI, MS and PD patients [205, 206]. Fesoterodine for SCI patients can diminish the magnitude and frequency of AD episodes [207]. Favourable results with the new drug imidafenacin have been reported in suprapontine as well as SCI patients [208, 209].

Side effects: Controlled-release antimuscarinics have some minor side effects, e.g. dry mouth [210]. It has been suggested that different ways of administration may help to reduce side effects [211]. Imidafenacine has been safely used in neurological patients with no worsening of cognitive function [208]. Nevertheless, the potential risk of developing dementia should be taken into account [212]; consider switching to beta-3 agonists or other therapies if cognition is affected [213].

Beta-3-adrenergic receptor agonists
Despite the increasing use of mirabegron in neuro urological patients, its role in these patients is still unclear [214, 215]. In MS and SCI patients, with very short follow-up, mirabegron has not demonstrated any significant effect on detrusor pressure or cystometric capacity [69, 216, 217], despite the reported improvement in LUT symptoms and quality of life similar to antimuscarinics [215]. Cardiovascular safety in NDO population has been suggested in a placebo-controlled RCT [218]. A significant subjective improvement in NDO symptoms has also been reported using lower dosages of mirabegron in patients affected by CNS lesions without any negative effects on voiding function [219]. A standard dosage of 50 mg has been found effective with no worsening of cognitive function in patients with PD [220].

Vibegron treatments significantly improved maximum cystometric capacity, bladder compliance, and NDO in a retrospective cohort study [221], but more studies are needed to do a recommendation.

Other drugs
A SR found that desmopressin may be effective for treating nocturnal polyuria in MS patients; however, adverse events were common, with the included studies being heterogeneous and of low quality [222].

Combination therapy with mirabegron and desmopressin in MS patients has shown promising results; however, clinical experience is still very limited in neuro-urological populations [223, 224].

In preliminary studies, improvements in daily incontinence rates, nocturia, daytime and 24-hour voids, as well as the low risk of adverse events, suggest that cannabinoids may be effective and safe in MS patients [225, 226]. A concomitant improvement in NDO symptoms has been reported in male MS patients using daily tadalafil to treat neurogenic erectile dysfunction (ED) [227].

3.4.2.3.2 Drugs for voiding symptoms
Detrusor underactivity: Cholinergic drugs, such as bethanechol and distigmine, have been considered to enhance detrusor contractility and promote bladder emptying, but are not frequently used in clinical practice [228]. Only preclinical studies have documented the potential benefits of cannabinoid agonists for improving detrusor contractility when administered intravesically [229, 230].

Decreasing bladder outlet resistance: α-blockers (e.g. tamsulosin, naftopidil and silodosin) seem to be effective for decreasing bladder outlet resistance, PVR and AD [231-235].

Increasing bladder outlet resistance: Several drugs have shown efficacy in selected cases of mild SUI, but there are no high-level evidence studies in neurological patients [134].

3.4.2.4 Summary of evidence and recommendations for drug treatments

<table>
<thead>
<tr>
<th>Summary of evidence</th>
<th>LE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Long-term efficacy and safety of antimuscarinic therapy for NDO is well documented.</td>
<td>1a</td>
</tr>
<tr>
<td>Mirabegron has shown similar symptom related clinical effects compared to antimuscarinics.</td>
<td>1b</td>
</tr>
<tr>
<td>Mirabegron does not improve urodynamic parameters in NDO patients.</td>
<td>1a</td>
</tr>
<tr>
<td>Maximise outcomes for NDO by considering combination therapy</td>
<td>3</td>
</tr>
</tbody>
</table>
Recommendations | Strength rating
--- | ---
Use antimuscarinic therapy as the first-line medical treatment for neurogenic detrusor overactivity. | Strong
Do not use mirabegron with the intention of reducing urodynamically proven neurogenic detrusor overactivity. | Strong
Prescribe α-blockers to decrease bladder outlet resistance. | Strong
Do not prescribe parasympathomimetics for underactive detrusor. | Strong

3.4.2.5 **Minimally invasive treatment**

3.4.2.5.1 Catheterisation

Intermittent self- or third-party catheterisation [236, 237] is the preferred management for neuro-urological patients who cannot effectively empty their bladders [134]. An adequate hand function is an independent risk factor for cessation of intermittent catheterisation (IC) [238].

It has not yet been established whether or not the incidence of UTI, other complications and user satisfaction are affected by either sterile, aseptic or clean IC, coated or uncoated catheters or by any other catheter type [239].

Sterile IC cannot be considered a routine procedure [134, 240] and careful counselling should be employed before commencing IC. In those with MS, commencing IC increases UTI rate over one year by seven fold, without improvement in QoL or symptom score [241]. In addition, in those with SCI, dissatisfaction (and discontinuation) is associated with increased UTI frequency, as well as being of the female sex [242]. It is worth considering patient satisfaction and subsequent compliance when instigating and continuing IC. Shared decision making is imperative, as although IC has better medical outcomes than indwelling catheterisation, in the SCI population it is associated with worse reported QoL compared to indwelling catheters, especially if recurrent (> 4 per year) UTIs complicate management [61, 243]. The use of hydrophilic catheters is associated with a lower rate of UTI [244]. An observational study found that of the 56.9% of patients who used IC 42.1% of patients discontinued IC within 12 months with inconvenience (36%), leakage (20%) and increased infections (19%) listed as the main reasons for the discontinuation [243].

To minimise the risk of UTI in neuro-urological patients, it is important that patient should be adequately taught to self-catheterise [134, 245-249]. The average frequency of catheterisations per day is four to six times [250] and the catheter size most often used is between 12-16 Fr. In aseptic IC, an optimum frequency of five times showed a reduction of UTI [250]. Ideally, bladder volume at catheterisation should, as a rule, not exceed 400-500 mL.

Indwelling transurethral catheterisation and, to a lesser extent, suprapubic cystostomy are associated with a range of complications as well as an enhanced risk for UTI [134, 251-258]; therefore, both procedures should be avoided, when possible. Silicone catheters are preferred as they are less susceptible to encrustation and because of the high incidence of latex allergy in the neuro-urological patient population [259].

Bladder cancer might be an increased risk in the general population with an indwelling catheter including neuro-urological patients, and clinicians should promptly investigate patients with the standard red flags for bladder cancer [258, 260].

3.4.2.5.2 Summary of evidence and recommendations for catheterisation

<table>
<thead>
<tr>
<th>Summary of evidence</th>
<th>LE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intermittent catheterisation is the standard treatment for patients who are unable to empty their bladder.</td>
<td>3</td>
</tr>
<tr>
<td>Indwelling transurethral catheterisation and suprapubic cystostomy are associated with a range of complications as well as an enhanced risk for UTI.</td>
<td>3</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Strength rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>Use intermittent catheterisation as a standard treatment for patients who are unable to empty their bladder.</td>
<td>Strong</td>
</tr>
<tr>
<td>Thoroughly instruct patients in the technique and risks of intermittent catheterisation.</td>
<td>Strong</td>
</tr>
<tr>
<td>Avoid indwelling transurethral and suprapubic catheterisation whenever possible.</td>
<td>Strong</td>
</tr>
</tbody>
</table>
3.4.2.5.3 Intravesical drug treatment

To reduce NDO, antimuscarinics can also be administered intravesically [261]. The efficacy and tolerability of intravesical administration of oxybutynin hydrochloride for treatment of NDO has been demonstrated in a recent randomised controlled study [211]. This approach may reduce adverse effects due to the fact that the antimuscarinic drug is metabolised differently [262] and a greater amount is sequestered in the bladder, even more than with electromotive administration [263].

The vanilloids, capsaicin and resiniferatoxin, desensitise the C-fibres for a period of a few months [264, 265]. Clinical studies have shown that resiniferatoxin has limited clinical efficacy compared to botulinum toxin A injections in the detrusor [264].

Although preliminary data suggest that intravesical vanilloids might be effective for treating neurological LUT dysfunction, their safety profile appears to be unfavourable [222]. Currently, there is no indication for the use of these substances, which are not licensed for intravesical treatment.

3.4.2.5.4 Summary of evidence and recommendations for intravesical drug treatment

<table>
<thead>
<tr>
<th>Summary of evidence</th>
<th>LE</th>
</tr>
</thead>
<tbody>
<tr>
<td>A significant reduction in adverse events was observed for intravesical administration of oxybutynin compared to oral administration.</td>
<td>1a</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Recommendation</th>
<th>Strength rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>Offer intravesical oxybutynin to neurogenic detrusor overactivity patients with poor tolerance to the oral route.</td>
<td>Strong</td>
</tr>
</tbody>
</table>

3.4.2.5.5 Botulinum toxin injections in the bladder

Botulinum toxin A causes a long-lasting but reversible chemical denervation that lasts for about nine months [266, 267]. The toxin injections are mapped over the detrusor in a dosage that depends on the preparation used. Botulinum toxin A has been proven effective in patients with neuro-urological disorders due to MS, SCI and PD in multiple RCTs and meta-analyses [268-271]. In mid- to long-term follow-up, 50%-70% of the patients continue botulinum toxin treatment [272-274]. Urodynamic studies might be necessary after treatment in order to monitor the effect of the injections on bladder pressure [275]. Repeated injections seem to be possible without loss of efficacy, even after initial low response rates, based on years of follow-up [266, 276-279]. The clinical efficacy of botulinum toxin A injection in patients with low morbidity after failure of augmentation enterocystoplasty has been demonstrated [280, 281]. The effectiveness of the different toxin variations seems to be comparable [282, 283]. A switch between different toxin variations may improve responsiveness [284].

The most frequent side effects are UTIs, urinary retention and haematuria [285]. Intermittent catheterisation may become necessary, this is especially relevant in MS patients as they do not often perform IC prior to intravesical botulinum toxin injections. However, a lower dose of botulinum toxin A (100 U) may reduce the rate of IC in MS patients [286]. Rare complications include generalised muscle weakness and AD [285]. Including the trigone has been suggested to be more effective than trigone-sparing injection [287]. Current research focuses on different delivery approaches to injection such as liposome encapsulated botulinum toxin to decrease side effects [288]. Neuro-urological patients with an indwelling catheter and concomitant bladder pain and/or catheter bypass leakage could benefit from intravesical botulinum injections [289].

3.4.2.5.6 Bladder neck and urethral procedures

*Reduction of the bladder outlet resistance:* This may be necessary to protect the UUT. This can be achieved by chemical denervation of the sphincter or by surgical interventions (bladder neck or sphincter incision or urethral stent – Section 3.4.3.1). However, high rates of long-term complications are still noted after the procedures. Patients should be fully aware about the high risk of urinary incontinence which can be the main reason of dissatisfaction although its management with external devices [290] (Section 3.4.2.1).
• **Botulinum toxin A**: This can be used to treat DSD effectively by injecting the sphincter at a dose that depends on the preparation used. An improvement of patient reported outcomes has been described in DSD patients with cervical, incomplete SCI, detrusor overactivity and partial hand function [291]. Detrusor sphincter dyssynergia is abolished only for a few months, necessitating repeat injections. The benefit of this treatment has been reported to be limited with mild AEs [292]. However, a recent SR concluded that, because of limited evidence, future RCTs assessing the effectiveness of botulinum toxin A injections also need to address the uncertainty about the optimal dose and mode of injection [293]. In addition, this therapy is not licensed.

• **Increasing bladder outlet resistance**: This can improve the continence condition. However, despite early positive results with urethral bulking agents, a relative early loss of continence is reported in patients with neuro-urological disorders [134, 294, 295].

• **Urethral inserts**: Urethral plugs or valves for the management of (female) stress incontinence have not been applied in neuro-urological patients. The experience with active pumping urethral prosthesis for treatment of the underactive or acontractile detrusor were disappointing [296].

### 3.4.2.5.7 Summary of evidence and recommendations for botulinum toxin A injections

<table>
<thead>
<tr>
<th>Summary of evidence</th>
<th>LE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Botulinum toxin A has been proven effective in patients with neuro-urological disorders due to MS or SCI in multiple RCTs and meta-analyses.</td>
<td>1a</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Strength rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>Use botulinum toxin injection in the detrusor to reduce neurogenic detrusor overactivity in multiple sclerosis or spinal cord injury patients if antimuscarinic therapy is ineffective.</td>
<td>Strong</td>
</tr>
</tbody>
</table>

### 3.4.3 Surgical treatment

There is considerable heterogeneity in outcome parameters and definitions of cure used to report on outcomes of surgical interventions for SUI in neuro-urological patients [297]. The heterogeneity of outcome reporting makes it difficult to interpret and compare different studies and therapies. A consistent comparison of the outcomes of therapy can only be made after standardisation of outcome parameters and definitions of cure or success; therefore, it would seem prudent to develop a core outcome set (COS) for use in UI research in neuro-urological patients [297]. Until such a COS is developed it would seem feasible to use both a subjective and objective outcome parameter and the combination of both to define cure [297]. Due to the importance of QoL for neuro-urological patients a disease-specific QoL questionnaire or a validated bother questionnaire validated for neuro-urological patients should be used as the subjective outcome parameter [297].

#### 3.4.3.1 Bladder neck and urethral procedures to improve neurogenic stress urinary incontinence

Procedures to treat neurogenic stress urinary incontinence (N-SUI) are suitable only when the risk for upper urinary tract deterioration and detrusor pressures can be controlled. A simultaneous therapy of bladder management may be necessary [298].

• **Urethral sling**: Various materials have been used for this procedure with enduring positive results. The procedure is established in women with the ability to self-catheterise [298-303]. There is growing evidence that female synthetic mid-urethral slings (MUS) can be used effectively with acceptable medium to long-term results and minimal morbidity in neuro-urological patients [300, 301]. Autologous pubovaginal sling has been considered the procedure of choice for treating female N-SUI and it should be preferred when concomitant bladder augmentation is also indicated [300]. Compared to transobturator, the retropubic route has been suggested to be more effective in women with N-SUI [301]. However, either for both synthetic MUS as well as autologous sling additional bladder management may become necessary due to the risk of “de novo” LUTS [300-302]. Complications include the need to perform IC especially after retropubic approach, mesh erosion or extrusion requiring partial or total removal, and retropubic haematoma and the 5-year failure rate is relevant [300, 301]. In men, both autologous and synthetic slings have been investigated less frequently compared to women and mainly in patients already on IC regimen before surgery [300]. The cure rate ranged from 29% to 71% at a follow-up of 12 to 36 months. Complications included haematoma, tape infection or erosion into urethra and difficulty to perform IC [300].
• **Artificial urinary sphincter (AUS):** This device was introduced by Light and Scott for male patients with N-SUI [304]. It has stood the test of time and acceptable long-term outcomes can be obtained [305]. Implantation of AUS is the most often performed procedure for N-SUI especially in men with a high success/improvement rate [300]. However, the complication and re-operation rates are higher than in non-neurogenic SUI (up to 60%), so it is advisable that patients are conscientiously informed about the success rates as well as the possible need for re-intervention [306, 307]. In a case series with 25 years follow-up only 7.1% of patients were revision free at twenty years [308]. Re-interventions are commonly due to mechanical failure, urethral atrophy or erosion and infection. There is growing interest in the use of this device with development of laparoscopic and robot-assisted approaches via an anterior or a posterior access to the bladder neck [309, 310]. Nonetheless, careful patient selection and appropriate preoperative investigation are crucial [310]. Although from a single institution series, long-term surgical results are now available and support the potentially prominent role of AUS placement in female patients with N-SUI [300, 311-313]. Long-term surgical and patient-reported outcomes are needed to determine the role of AUS placement in female patients with N-SUI [311].

• **Adjustable continence device – (inflatable balloons):** The efficacy of this device has been reported mainly in post-prostatectomy incontinence (non-neurogenic male lower urinary tract symptoms EAU guidelines – Section 5.6.5.3.2). A similar cure and improvement rate has been reported in neurological patients when compared to non-neurological patients [314, 315]. However, it is associated with a low safety profile due to the high complication and limited device survival rate [316].

• **Bladder neck and urethra reconstruction:** The classical Young-Dees-Leadbetter procedure [317] for bladder neck reconstruction in children with bladder exstrophy, and Kropp urethra lengthening [318] improved by Salle [319], are established methods to restore continence provided that IC is practiced and/or bladder augmentation is performed [134, 320].

**Endoscopic techniques for treating anatomic bladder outlet obstruction [321]:**

• **Transurethral resection of the prostate** is indicated in male patients with refractory LUT symptoms due to benign prostatic obstruction. Special consideration should be given to pre-operative abnormal sphincter function and the type of neurological disease, which can lead to persistent or "de novo" LUTS [322, 323].

• **Urethrotomy** is indicated in patients with urethral strictures. Cold knife or neodymium:YAG contact laser urethrotomy at the twelve o'clock position can be performed [324, 325].

• **Urethroplasty** should be performed on an individual basis depending on the urethral lesion (erosion, stricture, diverticula, fistula), length and location. However urethral surgery in neurological patients has a high failure rate and in recurrent strictures, urinary diversion should be considered [326].

• **Sphincterotomy** has been shown to be an efficient technique for the resolution of AD, hydronephrosis and recurrent UTI, and for decreasing detrusor pressure, PVR and vesicoureteral reflux. It is irreversible and should be limited to men who are able to wear a condom catheter. By staged incision, bladder outlet resistance can be reduced without completely losing the closure function of the urethra [133, 134, 327]. The incision with less complications, is the twelve o'clock sphincterotomy with cold knife [328] or neodymium:YAG laser [329]. Sphincterotomy needs to be repeated at regular intervals in many patients [330], but it is efficient and does not cause severe adverse effects [133, 331]. Secondary narrowing of the bladder neck may occur, for which combined bladder neck incision might be considered [332].

• **Bladder neck incision:** This may be indicated for anatomical or functional bladder neck obstruction [290, 293, 321, 323].

• **Stents:** Implantation of urethral stents results in continence being dependent on adequate closure of the bladder neck [134]. The results are comparable with sphincterotomy and the stenting procedure has a shorter duration of surgery and hospital stay [333, 334]. However, the costs [133], possible complications and re-interventions [335, 336] are limiting factors in their use [337-340].
3.4.3.2 Denervation, deafferentation, sacral neuromodulation

Sacral anterior root stimulation (SARS) is aimed at producing detrusor contraction. The technique was developed by Brindley [341] and is only applicable to complete lesions above the implant location, as its stimulation amplitude is over the pain threshold. The urethral sphincter efferents are also stimulated, but because the striated muscle relaxes faster than the smooth muscle of the detrusor, so-called “post-stimulus voiding” occurs. This approach has been successful in highly selected patients [342-345]. Although it has been shown that detrusor pressure during SARS decreases over time, the changes do not seem to be clinically relevant during the first decade after surgery [346]. By changing the stimulation parameters, this method can also induce defecation or erection. A recent study reported that Charcot spinal arthropathy should be considered as a potential long-term complication of SARS, leading to spinal instability and to SARS dysfunction [347].

Sacral rhizotomy, also known as sacral deafferentation, has achieved some success in reducing NDO [348-350], but nowadays, it is used mostly as an adjuvant to SARS [342, 351-354]. Alternatives to rhizotomy are sought in this treatment combination [355-357].

There is growing evidence, including one RCT [358], on the use of sacral neuromodulation for treating neuro-urological symptoms, but due to the paucity of disease specific studies it remains unclear which neurological patients are most suitable [359-361]. MS patients with NDO have been often reported as good responders to several types of neuromodulations [361-363]. The neuromodulation effect on urodynamic parameters is still unclear [364]. With the development of MRI-compatible pulse generators and leads, the avoidance of this procedure in patients needing this imaging technique for their follow-up is no longer required.

Other neuromodulation techniques like the deep brain stimulation in PD patients may have beneficial effects in the LUT but these depend on the site of stimulation and although prospective, specifically designed studies are needed in neuro-urological patients [365, 366].

3.4.3.3 Bladder covering by striated muscle

When the bladder is covered by striated muscle, that can be stimulated electrically, or ideally that can be contracted voluntarily, voiding function can be restored to an acontractile bladder. The rectus abdominis [367] and latissimus dorsi [368] have been used successfully in neuro-urological patients [369, 370].

3.4.3.4 Bladder augmentation

The aim of auto-augmentation (detrusor myectomy) is to reduce NDO or improve bladder compliance. The advantages are low surgical burden, low rate of long-term adverse effects, positive effect on patient QoL, and it does not preclude further interventions [133, 298, 371-374].

Replacing or expanding the bladder by intestine ensures a low-pressure reservoir improving bladder compliance and abolishing or at least reducing NDO [375, 376]. Improved QoL and stable renal function has been reported during long-term follow-up in SCI and SB patients [377-379]. It is not clear whether augmented cystoplasty should be combined with simultaneous ureter reimplantation when high grade VUR is present [379, 380]. Patients performing IC with augmented cystoplasty had better urinary function and satisfaction with their urinary symptoms compared to patients performing IC with or without botulinum toxin treatment [381]. Long-term complications includes bladder perforation (1.9%), mucus production (12.5%), metabolic abnormalities (3.35%), bowel dysfunction (15%), and stone formation (10%) [377].

The procedure should be used with caution in neuro-urological patients but may become necessary if all less-invasive treatment methods have failed. Special attention should be paid to patients with pre-operative renal scars since metabolic acidosis can develop [382]. Supratrigonal cystectomy [376, 383], is indicated in patients with a severely thick and fibrotic bladder wall. Intermittent catheterisation may become necessary after this procedure. The long-term scientific evidence shows that bladder augmentation is a highly successful procedure that stabilises renal function and prevents anatomical deterioration; however, lifelong follow-up is essential in this patient group given the significant morbidity associated with this procedure [377, 384, 385].

3.4.3.5 Urinary diversion

When no other therapy is successful, urinary diversion must be considered for the protection of the UUT [298].

Continent diversion: This should be the first choice for urinary diversion. Patients with limited dexterity or anatomical barriers (e.g., urethral strictures, women with poor mobility and/or obesity) may prefer a stoma instead of using the urethra for catheterisation. For cosmetic reasons, the umbilicus is often used for the stoma site [386-392]. A SR of the literature concluded that continent catheterisable tubes/stomas are an effective treatment option in neuro-urological patients unable to perform intermittent self-catheterisation through the urethra [393]. The positive impact on QoL comprised sexual life improvement, better body image, high satisfaction rates in urologic management, independence, time saved on catheterisation, and better capacity to perform daily activity and work [394]. However, the complication rates were significant with 85/213 post-
operative events requiring re-operation [393]. Tube stenosis occurred in 4-32% of the cases. Complications related to concomitant procedures (augmentation cystoplasty, pouch) included neovesicocutaneous fistulae (3.4%), bladder stones (20-25%), and bladder perforations (up to 40% in one case series) [393].

**Incontinent diversion:** If catheterisation is impossible, incontinent diversion with a urine-collecting device is indicated. Ultimately, it could be considered in selected patients with intractable and untreatable incontinence, in patients with LUT destruction, when the UUT is severely compromised, and in patients who refuse other therapy [134]. An ileal segment is used for the diversion in most cases [134, 395-398]. Patients gain better functional status and QoL after surgery [399]. Moreover, to achieve a high satisfaction rate, it is necessary to involve relatives and caregivers with stoma management. Concomitant cystectomy to avoid pyocystitis may be advisable [400]. All procedures can be done open, laparoscopically as well as robotically [401-403]. However, prospective comparative studies are lacking [402, 404].

**Undiversion:** Long-standing diversions may be successfully undiverted or an incontinent diversion changed to a continent one with the emergence of new and better techniques for control of detrusor pressure and incontinence [134]. The patient must be carefully counselled and must comply meticulously with the instructions [134]. Successful undiversion can then be performed [405].

In a prospective observational study (n=1,479), QoL was investigated in neuro-urological patients using four different bladder management options. It is the first study to focus on PROMS and noted that surgery was associated with fewer bladder management difficulties and a better QoL [61].

### 3.4.3.6 Summary of evidence and recommendations for surgical treatment

<table>
<thead>
<tr>
<th>Summary of evidence</th>
<th>LE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bladder augmentation is an effective option to decrease detrusor pressure and increase bladder capacity, when all less-invasive treatment methods have failed.</td>
<td>3</td>
</tr>
<tr>
<td>Urethral sling placement is an established procedure, with acceptable mid- to long-term results, in women with the ability to self-catheterise.</td>
<td>3</td>
</tr>
<tr>
<td>Artificial urinary sphincter insertion is the most frequently offered option to treat neurogenic SUI with acceptable long-term outcomes, in males. The complication and re-operation rates are higher in neuro-urological patients; therefore, patients must be adequately informed regarding the success rates as well as the complications that may occur following the procedure.</td>
<td>3</td>
</tr>
<tr>
<td>Sacral neuromodulation is an effective and safe option in the treatment of selective neurogenic LUT dysfunction.</td>
<td>1b</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Strength rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>Offer bladder augmentation in low bladder compliance and/or refractory neurogenic detrusor overactivity.</td>
<td>Strong</td>
</tr>
<tr>
<td>Place an autologous urethral sling as first-line treatment in female patients with neurogenic stress urinary incontinence (SUI) who are able to self-catheterise.</td>
<td>Strong</td>
</tr>
<tr>
<td>Place a synthetic urethral sling, as an alternative to autologous urethral slings, in selected female patients with neurogenic SUI who are able to self-catheterise.</td>
<td>Weak</td>
</tr>
<tr>
<td>Insert an artificial urinary sphincter in selected female patients with neurogenic SUI; however, patients should be referred to experienced centres for the procedure.</td>
<td>Weak</td>
</tr>
<tr>
<td>Insert an artificial urinary sphincter in male patients with neurogenic SUI.</td>
<td>Strong</td>
</tr>
<tr>
<td>Consider sacral neuromodulation in selected neuro-urological patients.</td>
<td>Strong</td>
</tr>
</tbody>
</table>

### 3.5 Urinary tract infection in neuro-urological patients

#### 3.5.1 Epidemiology, aetiology and pathophysiology

Urinary tract infection is the onset of signs and/or symptoms accompanied by laboratory findings of a UTI (bacteriuria, leukocyturia and positive urine culture) [387]. There are no evidence-based cut-off values for the quantification of these findings [406]. The published consensus is that a significant bacteriuria in persons performing IC is present with > 102 cfu/mL, > 104 cfu/mL in clean-void specimens and any detectable concentration in suprapubic aspirates. Regarding leukocyturia, ten or more leukocytes in centrifuged urine samples per microscopic field (400x) are regarded as significant [387].
The pathogenesis of UTI in neuro-urological patients is multifactorial. Male gender seems to be a risk factor for febrile and recurrent UTIs [407, 408]. Several etiological factors have been described: altered intrinsic defence mechanisms, impaired washout and catheterisation [409-412]. Poor glycemic control has also been established as a risk factor for UTI in women with type 1 diabetes [413]. However, the exact working mechanisms remain unknown. The presence of asymptomatic bacteriuria in SCI patients is higher than in the general population and varies depending on bladder management. Prevalence of bacteriuria in those performing clean IC varies from 23%-89% [414]. Sphincterotomy and condom catheter drainage has a 57% prevalence [415]. Asymptomatic bacteria should not be routinely screened for in this population [416] but a nomogram can be a helpful tool for early prediction of UTIs [417].

Individuals with neuro-urological symptoms, especially those with SCI, may have other signs and symptoms in addition to or instead of traditional signs and symptoms of a UTI in able-bodied individuals [418]. Other problems, such as AD, may develop or worsen due to a UTI [244]. The most common signs and symptoms suspicious of a UTI in those with neuro-urological disorders are fever, new onset or increase in incontinence, including leaking around an indwelling catheter, increased spasticity, malaise, lethargy or sense of unease, cloudy urine with increased urine odour, discomfort or pain over the kidney or bladder, dysuria, or AD [244, 419]. New incontinence is the most specific symptom, whereas cloudy and foul-smelling urine has the highest positive predictive value for UTI diagnosis [420].

3.5.2 **Diagnostic evaluation**

Urine culture and urinalysis are the optimum tests for the diagnosis of UTI in neuro-urological patients. A dipstick test is more useful to exclude rather than to prove UTI [421, 422] and is not recommended. As bacterial strains and resistance patterns in persons with neuro-urological disorders may differ from those of able-bodied patients, microbiologic testing is mandatory [423]. Neuro-urological disorders may differ from those of able-bodied patients, microbiologic testing is mandatory [400].

3.5.3 **Disease management**

Bacteriuria in patients with neuro-urological disorders should not be treated. Treatment of asymptomatic bacteriuria results in significantly more resistant bacterial strains without improving the outcome [424]. Urinary tract infections in persons with neuro-urological disorders are by definition a complicated UTI; therefore, single-dose treatment is not advised. There is no consensus in the literature about the duration of treatment as it depends on the severity of the UTI and the involvement of the kidneys and the prostate. Generally, a five to seven day course of antibiotic treatment is advised, which can be extended up to fourteen days according to the extent of the infection [424]. The choice of antibiotic therapy should be based on the results of the microbiologic testing. If immediate treatment is mandatory (e.g., fever, sepsicaemia, intolerable clinical symptoms, extensive AD), the choice of treatment should be based on local and individual resistance profiles, as well as on results from previous urine cultures [425]. In patients with afebrile UTI, an initial non-antibiotic treatment may be justified [426, 427].

3.5.3.1 **Recurrent UTI**

Recurrent UTI in patients with neuro-urological disorders may indicate suboptimal management of the underlying functional problem, e.g., high bladder pressure during storage and voiding, incomplete voiding or bladder stones. The improvement of bladder function, by treating NDO by botulinum toxin A injection in the detrusor [428], and the removal of bladder stones or other direct supporting factors, especially indwelling catheters, as early as possible, are mandatory [423].

3.5.3.2 **Prevention**

If the improvement of bladder function and removal of foreign bodies/stones is not successful, additional UTI prevention strategies should be utilised. In a meta-analysis the use of hydrophilic catheters was associated with a lower rate of UTI [244].

Various medical approaches have been tested for UTI prophylaxis in patients with neuro-urological disorders. The benefit of cranberry juice or probiotics for the prevention of UTI could not be demonstrated in RCTs [429, 430]. Methenamine hippurate is not effective in individuals with neuro-urological symptoms [431]. There is no sufficient evidence to support the use of L-methionine for urine acidification to prevent recurrent UTIs [432]. There is only weak evidence that oral immunotherapy reduces bacteriuria in patients with SCI [433] and that recurrent UTIs are reduced [434]. Low-dose, long-term, antibiotic prophylaxis can reduce UTI frequency, but increases bacterial resistance and is therefore not recommended [435].
Weekly cycling of antibiotic prophylaxis provided long-term positive results, but the results of this trial need to be confirmed in further studies [436]. Another possible future option, the inoculation of apathogenic Escherichia coli strains into the bladder, has provided positive results in initial studies, but because of the paucity of data [437], cannot be recommended as a treatment option. There is initial evidence that homeopathic treatment can decrease UTI frequency [438].

The use of daily intravesical iodine washouts shows promising results for reduction of symptomatic UTIs and hospitalisation without increase in multi drug resistance in patients with NLUTD who perform IC [439]. Other intravesical agents have also been trialed for the reduction of UTIs, both antimicrobial and non. Intravesical gentamicin has been shown to reduce UTIs and oral antibiotic use, without increasing antimicrobial resistance [435, 440]. Intravesical hyaluronic acid was also reported in this metanalysis to reduce mean number of UTIs [441].

In summary, based on the criteria of evidence-based medicine, there is currently no preventive measure for recurrent UTI in patients with neuro-urological disorders that can be recommended without limitations. Therefore, individualised concepts should be taken into consideration, including immunostimulation, phytotherapy and complementary medicine [442]. Prevention of UTIs in patients with neuro-urological disorders is important to pursue, but since there are no data favouring one approach over another, prophylaxis is essentially a trial-and-error approach.

### 3.5.4 Summary of evidence and recommendations for the treatment of UTI

<table>
<thead>
<tr>
<th>Summary of evidence</th>
<th>LE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment of asymptomatic bacteriuria results in significantly more resistant bacterial strains without improving patient outcome.</td>
<td>1a</td>
</tr>
<tr>
<td>Low-dose, long-term, antibiotic prophylaxis can reduce UTI frequency, but increases bacterial resistance.</td>
<td>2a</td>
</tr>
<tr>
<td>Recurrent UTIs in patients with neuro-urological disorders may indicate suboptimal management of the underlying functional problem. Improvement of bladder function as early as possible is mandatory.</td>
<td>3</td>
</tr>
<tr>
<td>There is currently no preventive measure for recurrent UTI in patients with neuro-urological disorders that can be recommended without limitations.</td>
<td>3</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Strength rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>Do not use dipstick urine analysis to screen for urinary tract infection (UTI) in neuro-urological patients.</td>
<td>Strong</td>
</tr>
<tr>
<td>Do not screen for or treat asymptomatic bacteriuria in patients with neuro-urological disorders.</td>
<td>Strong</td>
</tr>
<tr>
<td>Avoid the use of long-term antibiotics for recurrent UTIs.</td>
<td>Strong</td>
</tr>
<tr>
<td>In patients with recurrent UTIs, optimise treatment of neuro-urological symptoms and remove foreign bodies (e.g., stones, indwelling catheters) from the urinary tract.</td>
<td>Strong</td>
</tr>
<tr>
<td>Individualise UTI prophylaxis in patients with neuro-urological disorders as there is no optimal prophylactic measure available.</td>
<td>Strong</td>
</tr>
</tbody>
</table>

### 3.6 Sexual function and fertility

This section specifically focuses on sexual dysfunction and infertility in patients with a neurological disease [443, 444]. Non-neurogenic, male sexual dysfunction and infertility are covered in separate EAU Guidelines [445, 446]. In neuro-urological patients sexual problems can be identified at three levels: primary (direct neurological damage), secondary (general physical disabilities) and tertiary (psychosocial and emotional issues) sexual dysfunction [447]. Adapting a systematic approach, such as the PLISSIT model (Permission, Limited Information, Specific Suggestions and Intensive Therapy) [448], provides a framework for counselling and treatment involving a stepwise approach to the management of neurogenic sexual dysfunction. Sexual dysfunction is associated with neurogenic LUT dysfunction in patients with MS [449] and SB [450]. Although various PROMs are available to evaluate sexual function, the evidence for good PROMs is limited and studies with high methodological quality are needed [77].
3.6.1 Erectile dysfunction

3.6.1.1 Phosphodiesterase type 5 inhibitors (PDE5Is)
Phosphodiesterase type 5 inhibitors (PDE5Is) are recommended as first-line treatment in neurogenic ED [443, 444]. In SCI patients, tadalafl, vardenafl and sildenafil have all improved retrograde ejaculation and improved erectile function and satisfaction on IIEF-15. Tadalafil 10 mg was shown to be more effective than sildenafil 50 mg. All currently available PDE5Is appear to be effective and safe, although there are no high-level evidence studies in neuro-urological patients investigating the efficacy and side effects across different PDE5Is, dosages and formulations [451].

For MS patients two studies reported significant improvement in ED when using sildenafil and tadalafil [444, 452] however, another study showed no improvement in ED with sildenafil [453]. One study found a significant improvement in ED in SB patients when using sildenafil [454].

In PD normal erectile function was described in over half of the patients using sildenafil 100 mg and a significant improvement in IIEF-15 score was found compared to placebo. While most neuro-urological patients require long-term therapy for ED some have a low compliance rate or stop therapy because of side effects [455, 456], most commonly headache and flushing [444]. In addition, PDE5Is may induce relevant hypotension in patients with tetraplegia/high-level paraplegia and multiple system atrophy [455, 456]. As a prerequisite for successful PDE5I-therapy, some residual nerve function is required to induce erection. Since many patients with SCI use on-demand nitrates for the treatment of AD, they must be counselled that PDE5Is are contraindicated when using nitrate medication.

3.6.1.2 Drug therapy other than PDE5Is
Fampridine to treat neurogenic spasticity has been shown to be beneficial in improving ED in two domains of the IIEF-15 in SCI and MS patients, however, with a significant discontinuation rate due to severe adverse events [457]. Sublingual apomorfine was shown to have poor results on ED in SCI patients and side-effects in half of the patients [458]. In PD, pergolide mesylate showed a significant improvement in IIEF-15 scores up to twelve months follow-up [459].

3.6.1.3 Mechanical devices
Mechanical devices (vacuum tumescence devices and penile rings) may be effective but are less popular [460-464].

3.6.1.4 Intracavernous injections and intraurethral application
Patients not responding to oral drugs may be offered intracavernous injections (alprostadil, papaverine and phentolamine) that have been shown to be effective in a number of neurological conditions, including SCI, MS, and diabetes mellitus [465-471], but their use requires careful dose titration and some precautions. Complications of intracavernous drugs include pain, priapism and corpora cavernosa fibrosis.

Intracavernous vasoactive drug injection is the first-line therapeutic option in patients taking nitrate medications, as well as those with concerns about drug interactions with PDE5Is, or in whom PDE5Is are ineffective. The impact of intracavernous injections on ejaculation and orgasmic function, their early use for increasing the recovery rate of a spontaneous erection, and their effectiveness and tolerability in the long-term are unclear [455]. Intra-urethral alprostadil application is an alternative, but less effective, route of administration [467, 472].

3.6.1.5 Sacral neuromodulation
Sacral neuromodulation for LUT dysfunction may improve sexual function; however, high level evidence studies are lacking.

3.6.1.6 Penile prostheses
Penile prostheses may be considered for treatment of neurogenic ED when all conservative treatments have failed. At a mean follow-up of seven years, 83.7% of patients with SCI were able to have sexual intercourse [444]. Serious complications, including infection and prosthesis perforation, may occur in about 10% of patients, depending on implant type [473-475].
3.6.1.7 Summary of evidence and recommendations for erectile dysfunction

<table>
<thead>
<tr>
<th>Summary of evidence</th>
<th>LE</th>
</tr>
</thead>
<tbody>
<tr>
<td>The long-term efficacy and safety of oral PDE5Is for the treatment of ED is well documented.</td>
<td>1b</td>
</tr>
<tr>
<td>Intracavernous vasoactive drug injections have been shown to be effective in a number of neurological conditions, including SCI and MS; however, their use requires careful dose titration and precautions.</td>
<td>3</td>
</tr>
<tr>
<td>Mechanical devices (vacuum tumescence devices and penile rings) may be effective but are less popular.</td>
<td>3</td>
</tr>
<tr>
<td>Reserve penile prostheses for selected patients, those in which all conservative treatments have failed, with neurogenic ED.</td>
<td>4</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Strength rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prescribe oral phosphodiesterase type 5 inhibitors as first-line medical treatment in neurogenic erectile dysfunction (ED).</td>
<td>Strong</td>
</tr>
<tr>
<td>Give intracavernous injections of vasoactive drugs (alone or in combination) as second-line medical treatment in neurogenic ED.</td>
<td>Strong</td>
</tr>
<tr>
<td>Offer mechanical devices such as vacuum devices and rings to patients with neurogenic ED.</td>
<td>Strong</td>
</tr>
</tbody>
</table>

3.6.2 Male fertility

Male fertility can be compromised in the neurological patient by ED, ejaculation disorder, impaired sperm quality or various combinations of these three disorders. Among the major conditions contributing to neurogenic infertility are pelvic and retroperitoneal surgery, diabetes mellitus, SB, MS and SCI [476]. Erectile dysfunction is managed as described previously. Retrograde ejaculation may be reversed by sympathomimetic agents contracting the bladder neck, including imipramine, ephedrine, pseudoephedrine, and phenylpropanolamine [476]. The use of a balloon catheter to obstruct the bladder neck may be effective in obtaining antegrade ejaculation [477]. If antegrade ejaculation is not achieved, the harvest of semen from the urine may be considered [478].

Prostatic massage is safe and easy to use for obtaining semen in men with lesions above Th 10 [479]. In several patients, vibrostimulation or transrectal electroejaculation are needed for sperm retrieval [476, 480, 481]. Semen retrieval is more likely with vibrostimulation in men with lesions above Th 10 [482-484]. In men with SCI, especially at or above Th 6, AD might occur during sexual activity and ejaculation [485, 486]; patients at risk and fertility clinics must be informed and aware of this potentially life-threatening condition. In SCI patients the use of oral midodrine can improve sperm retrieval at vibrostimulation [487].

In men with MS, use of disease modifying drugs during the conception phase, has not been associated with altered pregnancy outcomes [488]. Surgical procedures, such as, microsurgical epididymal sperm aspiration or testicular sperm extraction, may be used if vibrostimulation and electroejaculation are not successful [489, 490]. Pregnancy rates in patients with SCI are lower than in the general population, but since the introduction of intracytoplasmic sperm injection, men with SCI now have a good chance of becoming biological fathers [491-493].

3.6.2.1 Sperm quality and motility

The following has been reported on sperm quality and motility:

- bladder management with clean IC may improve semen quality compared to indwelling catheterisation, reflex voiding or bladder expression [494];
- in SCI patients sperm quality decreases at the early post-traumatic phase demonstrating lower spermatozoid vitality (necroospermia), reduced motility (asthenospermia) and leucospermia [489];
- long-term valproate treatment for epilepsy negatively influences sperm count and motility [495];
- vibrostimulation produces samples with better sperm motility than electrostimulation [496, 497];
- electro-ejaculation with interrupted current produces better sperm motility than continuous current [498];
- freezing of sperm is unlikely to improve fertility rates in men with SCI [499].
### 3.6.2.2 Summary of evidence and recommendations for male fertility

<table>
<thead>
<tr>
<th>Summary of evidence</th>
<th>LE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vibrostimulation and transrectal electroejaculation have been shown to be effective for sperm retrieval in neuro-urological patients.</td>
<td>1b</td>
</tr>
<tr>
<td>Surgical procedures, such as, microsurgical epididymal sperm aspiration or testicular sperm extraction, may be used if vibrostimulation and electroejaculation are not successful.</td>
<td>3</td>
</tr>
<tr>
<td>In men with SCI at or above Th 6, AD might occur during sexual activity and ejaculation.</td>
<td>3</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Strength rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>Perform vibrostimulation and transrectal electroejaculation for sperm retrieval in men with spinal cord injury.</td>
<td>Strong</td>
</tr>
<tr>
<td>Perform microsurgical epididymal sperm aspiration, testicular sperm extraction and intracytoplasmic sperm injection after failed vibrostimulation and/or transrectal electroejaculation in men with spinal cord injury.</td>
<td>Strong</td>
</tr>
<tr>
<td>Counsel men with spinal cord injury at or above Th 6 and fertility clinics about the potentially life-threatening condition of autonomic dysreflexia.</td>
<td>Strong</td>
</tr>
</tbody>
</table>

### 3.6.3 Female sexuality

The most relevant publications on neurogenic female sexual dysfunction are in women with SCI and MS, while there is only limited evidence for women with stroke and SB. After SCI, about 65-80% of women continue to be sexually active, but to a much lesser extent than before the injury, and about 25% report a decreased satisfaction with their sexual life [500-502]. Although sexual dysfunction is very common in women with MS, it is still often overlooked by medical professionals [503, 504]. A vast majority of female SB patients showed sexual dysfunction [505] and considered information about sexuality from their physicians insufficient [506]. Women with SCI reported dissatisfaction with the quality and quantity of sexuality-related rehabilitation services and were less likely to receive sexual information than men [507-509]. Similarly, majority of female stroke patients are not sexually satisfied [510].

The greatest physical barrier to sexual activity is UI. A correlation has been found between the urodynamic outcomes of low bladder capacity, compliance and high maximum detrusor pressure and sexual dysfunction in MS patients. Problems with positioning and spasticity affect mainly tetraplegic patients. Peer support may help to optimise the sexual adjustment of women with SCI in achieving a more positive self-image, self-esteem and feelings of being attractive to themselves and others [500, 511-513].

The use of specific drugs for sexual dysfunction is indicated to treat inadequate lubrication. Data on sildenafil for treating female sexual dysfunction are poor and controversial [444]. Although good evidence exists that psychological interventions are effective in the treatment of female hypoactive sexual desire disorder and female orgasmic disorder [514], there is a lack of high-level evidence studies in the neurological population.

Neurophysiological studies have shown that women with the ability to perceive Th 11-L2 pin-prick sensations may have psychogenic genital vasocongestion. Reflex lubrication and orgasm are more prevalent in women with SCI who have preserved the sacral reflex arc (S2-S5), even when it has not been shown in an individual woman that a specific level and degree of lesion is the cause of a particular sexual dysfunction. In SCI women with a complete lesion of the sacral reflex, arousal and orgasm may be evoked through stimulation of other erogenous zones above the level of lesions [507, 515, 516].

Sacral neuromodulation for LUT dysfunction may improve sexual function but high-evidence studies are lacking [444].

### 3.6.4 Female fertility

There are few studies on female fertility in neurological patients. More than a third (38%) of women with epilepsy had infertility and the relevant predictors were exposure to multiple (three or more) antiepileptic drugs, older age and lower education [517].
Although it seems that the reproductive capacity of women with SCI is only temporarily affected by SCI with cessation of menstruation for approximately six months after SCI [518], there are no high-level evidence studies. About 70% of sexually active women use some form of contraception after injury, but fewer women use the birth control pill compared to before their injury [519].

Women with SCI are more likely to suffer complications during pregnancy, labour and delivery compared to able-bodied women. Complications of labour and delivery include bladder problems, spasticity, pressure sores, anaemia, and AD [520-524]. Obstetric outcomes include higher rates of Caesarean sections and an increased incidence of low birth-weight babies [519, 522-524].

Epidural anaesthesia is chosen and effective for most patients with AD during labour and delivery [525, 526].

There is very little published data on women's experience of the menopause following SCI [527]. Women with MS who plan a pregnancy should evaluate their current drug treatment with their treating physician [528-530]. Clinical management should be individualised to optimise both the mother's reproductive outcomes and MS course [528, 529, 531].

3.6.4.1 Summary of evidence and recommendation for female sexuality and fertility

<table>
<thead>
<tr>
<th>Summary of evidence</th>
<th>LE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Data on specific drugs for treating female sexual dysfunction are poor and controversial.</td>
<td>4</td>
</tr>
<tr>
<td>There are limited numbers of studies on female fertility in neurological patients, clinical management should be individualised to optimise both the mother's reproductive outcomes and medical condition.</td>
<td>4</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Strength rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>Do not offer medical therapy for the treatment of neurogenic sexual dysfunction in women.</td>
<td>Strong</td>
</tr>
<tr>
<td>Take a multidisciplinary approach, tailored to individual patient's needs and preferences, in the management of fertility, pregnancy and delivery in women with neurological diseases.</td>
<td>Strong</td>
</tr>
</tbody>
</table>

3.7 Follow-up

3.7.1 Introduction

Neuro-urological disorders are often unstable, and the symptoms may vary considerably, even within a relatively short period. Regular follow-up is therefore necessary to assess the UUT [132].

Depending on the type of the underlying neurological pathology and the current stability of the neuro-urological symptoms, the interval between initial investigations and control diagnostics may vary and, in many cases, should not exceed one to two years. High-risk neuro-urological this interval should be much shorter. The UUT should be checked by ultrasonography at regular intervals in high-risk patients; about once every six months [6, 532]. In these patients, physical examination and urine laboratory should take place every year [6, 532]. In MS patients higher scores on the Expanded Disability Status Scale (EDSS) are associated with risk factors for UUT deterioration [533]. A urodynamic investigation should be performed as a diagnostic baseline, and repeated during follow-up, more frequently in high-risk patients [6, 532]. The bladder diary can aid in detecting MS patients that require urodynamic investigations [534]. In addition, bladder wall thickness can be measured on ultrasonography as an additional risk assessment for upper tract damage [535], although a 'safe' cut-off threshold for this has not been agreed [536]. The utility of DMSA (dimercaptosuccinic acid) for follow-up of neuro-urological patients has not been fully evaluated [537]. Any significant clinical change warrants further, specialised, investigation [6, 532]. However, there is a lack of high level evidence studies on this topic and every recommendation must be viewed critically in each individual neuro-urological patient [132].

The increased prevalence of muscle invasive bladder cancer in neuro-urological patients also warrants long-term follow-up [260]. The exact frequency of cystoscopy with or without cytology remains unknown, but presence of risk factors similar to the general population should trigger further investigation [538].

Adolescent patients with neurological pathology are at risk of being lost to follow-up during the transition to adulthood. It is important that a standardised approach during this transition is adopted to improve follow-up and specific treatment during adult life [539].
3.7.2  **Summary of evidence and recommendations for follow-up**

<table>
<thead>
<tr>
<th>Summary of evidence</th>
<th>LE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neuro-urological disorders are often unstable, and the symptoms may vary considerably; therefore, regular follow-up is necessary.</td>
<td>4</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Strength rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>Assess the upper urinary tract at regular intervals in high-risk patients.</td>
<td>Strong</td>
</tr>
<tr>
<td>Any significant clinical changes should instigate further, specialised, investigation.</td>
<td>Strong</td>
</tr>
<tr>
<td>Perform urodynamic investigation as a mandatory baseline diagnostic intervention in high-risk patients at regular intervals.</td>
<td>Strong</td>
</tr>
</tbody>
</table>

3.8  **Conclusions**

Neuro-urological disorders have a multifaceted pathology. They require an extensive and specific diagnosis before one can embark on an individualised therapy, which takes into account the medical and physical condition of the patient and the patient's expectations about their future. The urologist can select from a wealth of therapeutic options, each with its own pros and cons. Notwithstanding the success of any therapy embarked upon, close surveillance is necessary for the patient's entire life.

These Guidelines offer you expert advice on how to define the patient’s neuro-urological symptoms as precisely as possible and how to select, together with the patient, the appropriate therapy. This last choice, as always, is governed by the golden rule: as effective as needed, as non-invasive as possible.

4.  **REFERENCES**


https://pubmed.ncbi.nlm.nih.gov/28771936


https://pubmed.ncbi.nlm.nih.gov/28745818


https://link.springer.com/article/10.1007/s11884-022-00657-4


5. CONFLICT OF INTEREST

All members of the Neuro-urology working group have provided disclosure statements of all relationships that they have that might be perceived as a potential source of a conflict of interest. This information is publically accessible through the European Association of Urology website: http://uroweb.org/guideline. This guidelines document was developed with the financial support of the European Association of Urology. No external sources of funding and support have been involved. The EAU is a non-profit organisation and funding is limited to administrative and travel and meeting expenses. No honoraria or other reimbursements have been provided.

6. CITATION INFORMATION

The format in which to cite the EAU Guidelines will vary depending on the style guide of the journal in which the citation appears. Accordingly, the number of authors or whether, for instance, to include the publisher, location, or an ISBN number may vary.

The compilation of the complete Guidelines should be referenced as:

If a publisher and/or location is required, include:

References to individual guidelines should be structured in the following way:
Contributors’ names. Title of resource. Publication type. ISBN. Publisher and publisher location, year.